GPP
VNDA icon

Great Point Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Great Point Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-309,800
Closed -$5.22M – 44
2018
Q1 		$5.22M Sell
309,800
-487,731
-61% -$8.16M 0.78% 27
2017
Q4 		$12.1M Buy
797,531
+300,000
+60% +$4.45M 2.07% 21
2017
Q3 		$8.91M Sell
497,531
-1,734,707
-78% -$29M 1.73% 22
2017
Q2 		$36.4M Hold
2,232,238
– – 6.52% 3
2017
Q1 		$31.3M Buy
2,232,238
+222,238
+11% +$3.17M 6.21% 4
2016
Q4 		$32.1M Sell
2,010,000
-696,134
-26% -$11.2M 6.59% 3
2016
Q3 		$45M Buy
2,706,134
+376
+0% +$5.06K 11.49% 1
2016
Q2 		$30.3M Sell
2,705,758
-25,452
-0.9% -$246K 8.67% 2
2016
Q1 		$22.8M Buy
2,731,210
+631,109
+30% +$5.18M 8.19% 3
2015
Q4 		$19.6M Buy
2,100,101
+385,101
+22% +$3.84M 8.2% 4
2015
Q3 		$19.3M Buy
1,715,000
+301,401
+21% +$3.69M 7.65% 1
2015
Q2 		$17.9M Buy
1,413,599
+25,000
+2% +$270K 6.99% 3
2015
Q1 		$12.9M Buy
+1,388,599
New +$15.7M 5.68% 3

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Great Point Partners's VNDA Position: Q2 2018 in Review

Great Point Partners sold out of Vanda Pharmaceuticals (VNDA) in Q2 2018, closing a stake of 309,800 shares — an estimated $5.22M sold.

Great Point Partners first reported a position in VNDA in Q1 2015 and held it in 13 quarters. The position peaked at $45M in Q3 2016. 135 funds tracked by Wall St. Rank hold VNDA as of Q2 2018.

  • Great Point Partners reported no remaining Vanda Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Great Point Partners sold 309,800 Vanda Pharmaceuticals shares in Q2 2018, an estimated $5.22M.
  • Great Point Partners first reported a position in Vanda Pharmaceuticals in Q1 2015 and held it in 13 quarters.
  • Great Point Partners's Vanda Pharmaceuticals position peaked at $45M in Q3 2016.
  • 135 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2018.

Based on Great Point Partners's 13F filing for Q2 2018, filed 14 Aug 2018.